1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Odonate Therapeutics, Inc.

Odonate Therapeutics, Inc.

ODTC
Odonate Therapeutics, Inc.US flagOther OTC
22,005.00
USD
+5,005.00
- -
8.05BMarket Cap
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-470.24
-9,181.55
-97,452.38
-266,347.31
-279,562.5
-262,136.93
-142,027.03
- -
- -
-142,027.03
Free Cash Flow per Basic Share
-491.07
-5,157.74
-77,205.36
-206,589.82
-242,010
-235,605.81
-157,486.49
- -
- -
-157,486.49
Dividend per Share
- -
2,354.17
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
330.36
-19,184.52
-116,226.19
-383,257.49
-599,442.5
-759,460.58
-903,234.93
- -
- -
-903,234.93
Tangible Book Value per Share
330.36
6,794.64
583,279.76
371,269.46
405,750
282,458.51
123,209.98
- -
- -
123,209.98
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
-3
-33
-89
-112
-126
-68
43
7
-68
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
22.44
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
- -
2
195
122
159
133
59
48
57
59
LT Debt
- -
- -
- -
- -
2
5
4
2
2
4
Total Equity
- -
2
196
124
162
136
59
101
108
59
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
-0.59
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Jun'21
Sep'21
Dec'21
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
4
4
4
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
- -
- -
Market Capitalization
134
112
52

Working Capital

FRC

•

in mil. unless spec.
Jun'21
Sep'21
Dec'21
Total Current Assets
112
100
75
Cash, Cash Equivalents & STI
110
95
69
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
30
30
16
Payables & Accruals
26
29
15
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
7.13%
7.21%
Free Cash Flow
- -
61.77%
386.91%
Net Income, GAAP
- -
-50.61%
-82.94%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
-70,203.74
-45,769.23
-29,099.79
- -
-142,027.03
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Kevin C. Tang
Full Time Employees
137
Sector
Healthcare
Industry
Biotechnology
Address
3 East 28th Street New York City NY United States of America 10016
IPO Date
Dec 7, 2017
CIK
0001717452
Website
odonate.com
Similar Companies
Genocea Biosciences, Inc. (GNCA)
Valneva SE (0OB3.L)
Kadmon Holdings, Inc. (KDMN)
Avid Bioservices, Inc. (CDMO)
Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT)
Verastem, Inc. (2VSA.F)
Business
Odonate Therapeutics, Inc. was a pharmaceutical enterprise concentrated on addressing cancer, primarily advancing tesetaxel, an oral chemotherapy agent. This compound had progressed to a Phase III clinical study for individuals with metastatic breast cancer. However, following consultation with the U.S. Food and Drug Administration, the company determined in March 2021 that the available clinical data for tesetaxel was unlikely to secure regulatory approval. Consequently, Odonate Therapeutics ceased all development of tesetaxel and initiated a process to wind down its corporate activities. The company, established in 2013 and headquartered in New York, New York, subsequently had its shares delisted from The Nasdaq Stock Market in January 2022.